These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26951820)

  • 1. Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.
    Leitman EM; Hurst J; Mori M; Kublin J; Ndung'u T; Walker BD; Carlson J; Gray GE; Matthews PC; Frahm N; Goulder PJ
    J Infect Dis; 2016 Aug; 214(3):379-89. PubMed ID: 26951820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated HIV Infection of CD4 T Cells in MRKAd5 Vaccine Recipients Due to CD8 T Cells Targeting Adapted Epitopes.
    Qin K; Boppana S; Carlson JM; Fiore-Gartland A; Files J; Zeng J; Edberg J; Mailliard RB; Ochsenbauer C; Bansal A; Goepfert P
    J Virol; 2021 Jul; 95(16):e0016021. PubMed ID: 34076482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.
    Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK
    J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa.
    Brumme Z; Wang B; Nair K; Brumme C; de Pierres C; Reddy S; Julg B; Moodley E; Thobakgale C; Lu Z; van der Stok M; Bishop K; Mncube Z; Chonco F; Yuki Y; Frahm N; Brander C; Carrington M; Freedberg K; Kiepiela P; Goulder P; Walker B; Ndung'u T; Losina E
    Clin Infect Dis; 2009 Sep; 49(6):956-64. PubMed ID: 19663693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DQB1*06 and breadth of Nef core region-specific T-cell response are associated with slow disease progression in antiretroviral therapy-naive Chinese HIV-1 subtype B patients.
    Li W; Li C; Xia W; Li X
    Hum Vaccin Immunother; 2017 Oct; 13(10):2341-2347. PubMed ID: 28771107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HLA selection pressure on HIV fitness at a population level in Mexico and Barbados.
    Juarez-Molina CI; Payne R; Soto-Nava M; Avila-Rios S; Valenzuela-Ponce H; Adland E; Leitman E; Brener J; Muenchhoff M; Branch S; Landis C; Reyes-Teran G; Goulder P
    J Virol; 2014 Sep; 88(18):10392-8. PubMed ID: 25008926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.
    Matthews PC; Adland E; Listgarten J; Leslie A; Mkhwanazi N; Carlson JM; Harndahl M; Stryhn A; Payne RP; Ogwu A; Huang KH; Frater J; Paioni P; Kloverpris H; Jooste P; Goedhals D; van Vuuren C; Steyn D; Riddell L; Chen F; Luzzi G; Balachandran T; Ndung'u T; Buus S; Carrington M; Shapiro R; Heckerman D; Goulder PJ
    J Immunol; 2011 May; 186(10):5675-86. PubMed ID: 21498667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome.
    Streeck H; Lu R; Beckwith N; Milazzo M; Liu M; Routy JP; Little S; Jessen H; Kelleher AD; Hecht F; Sekaly RP; Alter G; Heckerman D; Carrington M; Rosenberg ES; Altfeld M
    J Virol; 2014 Nov; 88(21):12793-801. PubMed ID: 25165102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.
    Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.
    Casazza JP; Bowman KA; Adzaku S; Smith EC; Enama ME; Bailer RT; Price DA; Gostick E; Gordon IJ; Ambrozak DR; Nason MC; Roederer M; Andrews CA; Maldarelli FM; Wiegand A; Kearney MF; Persaud D; Ziemniak C; Gottardo R; Ledgerwood JE; Graham BS; Koup RA;
    J Infect Dis; 2013 Jun; 207(12):1829-40. PubMed ID: 23482645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expansion ability but not the quality of HIV-specific CD8(+) T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors.
    López M; Peris A; Soriano V; Lozano S; Vicario JL; Rallón NI; Restrepo C; Benito JM
    Immunology; 2011 Nov; 134(3):305-13. PubMed ID: 21978000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
    Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
    J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.
    Janes H; Friedrich DP; Krambrink A; Smith RJ; Kallas EG; Horton H; Casimiro DR; Carrington M; Geraghty DE; Gilbert PB; McElrath MJ; Frahm N
    J Infect Dis; 2013 Oct; 208(8):1231-9. PubMed ID: 23878319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition.
    Hayes PJ; Cox JH; Coleman AR; Fernandez N; Bergin PJ; Kopycinski JT; Nitayaphan S; Pitisuttihum P; de Souza M; Duerr A; Morgan C; Gilmour JW
    AIDS; 2016 Jul; 30(11):1703-12. PubMed ID: 27088318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure.
    Ngumbela KC; Day CL; Mncube Z; Nair K; Ramduth D; Thobakgale C; Moodley E; Reddy S; de Pierres C; Mkhwanazi N; Bishop K; van der Stok M; Ismail N; Honeyborne I; Crawford H; Kavanagh DG; Rousseau C; Nickle D; Mullins J; Heckerman D; Korber B; Coovadia H; Kiepiela P; Goulder PJ; Walker BD
    AIDS Res Hum Retroviruses; 2008 Jan; 24(1):72-82. PubMed ID: 18275350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIR3DL1-Negative CD8 T Cells and KIR3DL1-Negative Natural Killer Cells Contribute to the Advantageous Control of Early Human Immunodeficiency Virus Type 1 Infection in
    Zhang X; Lu X; Moog C; Yuan L; Liu Z; Li Z; Xia W; Zhou Y; Wu H; Zhang T; Su B
    Front Immunol; 2018; 9():1855. PubMed ID: 30147699
    [No Abstract]   [Full Text] [Related]  

  • 18. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.
    Janes H; Frahm N; DeCamp A; Rolland M; Gabriel E; Wolfson J; Hertz T; Kallas E; Goepfert P; Friedrich DP; Corey L; Mullins JI; McElrath MJ; Gilbert P
    PLoS One; 2012; 7(8):e43396. PubMed ID: 22952672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Effect of HLA-B*5701 and HLA-C -35 Genetic Variants in HIV-Positive Caucasians from Northern Poland.
    Leszczyszyn-Pynka M; Aksak-Wąs B; Urbańska A; Parczewski M
    PLoS One; 2015; 10(6):e0127867. PubMed ID: 26068923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.
    Emu B; Sinclair E; Hatano H; Ferre A; Shacklett B; Martin JN; McCune JM; Deeks SG
    J Virol; 2008 Jun; 82(11):5398-407. PubMed ID: 18353945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.